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Introduction
Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) typically presents with a sudden onset fol-
lowing an infection. Key symptoms are debilitating and long-lasting fatigue, combined with postexertion-
al malaise causing prolonged exacerbated symptom burden after physical or mental overactivity. ME/CFS 
affects multiple organ systems, and additional symptoms include unrefreshing sleep, cognitive problems 
(referred to as brain fog), autonomic dysfunction, sensory hypersensitivity, and widespread pain (1, 2). Using 
the Canadian consensus criteria (1), the prevalence of  ME/CFS is 0.1%–0.8% in both adults and children 
(3–5). Patients recovering from SARS-CoV-2 infection (COVID-19) may develop ME/CFS-like illness (“long 
COVID”; refs. 6, 7). While the etiology of  ME/CFS is still unknown, accumulating evidence documents 
measurable biological changes in the blood of  patients with ME/CFS. A deeper understanding of  the under-
lying biological mechanisms is urgently required to meet this major health challenge.
ME/CFS has been suggested to be triggered by an aberrant immune response, with possible roles for 
autoimmunity, immune dysregulation, and inflammation (8–13). Pathological effects reported in the patients 
include neuroinflammation, neuroendocrine abnormalities, autonomic nervous system abnormalities, dis-
turbed energy metabolism, and immunological changes (14). Such effects are inherently connected through 
Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a debilitating disease usually 
presenting after infection. Emerging evidence supports that energy metabolism is affected in ME/
CFS, but a unifying metabolic phenotype has not been firmly established. We performed global 
metabolomics, lipidomics, and hormone measurements, and we used exploratory data analyses to 
compare serum from 83 patients with ME/CFS and 35 healthy controls. Some changes were common 
in the patient group, and these were compatible with effects of elevated energy strain and altered 
utilization of fatty acids and amino acids as catabolic fuels. In addition, a set of heterogeneous 
effects reflected specific changes in 3 subsets of patients, and 2 of these expressed characteristic 
contexts of deregulated energy metabolism. The biological relevance of these metabolic phenotypes 
(metabotypes) was supported by clinical data and independent blood analyses. In summary, we 
report a map of common and context-dependent metabolic changes in ME/CFS, and some of them 
presented possible associations with clinical patient profiles. We suggest that elevated energy 
strain may result from exertion-triggered tissue hypoxia and lead to systemic metabolic adaptation 
and compensation. Through various mechanisms, such metabolic dysfunction represents a likely 
mediator of key symptoms in ME/CFS and possibly a target for supportive intervention.
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multifaceted physiological cues at molecular, cellular, and systemic levels. We hypothesize that impaired 
metabolism and strain on cellular energetics may play a central role. Functional evidence supports the exis-
tence of  ME/CFS serum factors that stress cell metabolism in vitro (15–17). Despite the fact that metabolic 
blood parameters usually are within the normal ranges in patients with ME/CFS (18), studies have indicated 
subclinical abnormalities and metabolic shifts that may have biological relevance. For example, significant or 
trending changes in blood glucose and lipids have been reported (19–23). Such effects may suggest that sys-
temic control of  energy fuel storage, mobilization, and utilization is affected in patients with ME/CFS, but a 
consensus phenotype regarding energy metabolism has not been established yet.
Untargeted metabolomics studies have found alterations that associate with the disease (20, 21, 24–26). 
The reported metabolite patterns are generally compatible with disturbed cellular energetics, although the 
affected metabolites vary somewhat between the studies. Furthermore, the relatively large data heterogene-
ity often seen within ME/CFS cohorts may indicate the presence of  context-dependent individual effects. 
However, the notion that impaired energy metabolism is implicated in ME/CFS is further supported by tar-
geted high-confidence studies that show changes related to key pathways such as the tricarboxylic acid (TCA) 
cycle and amino acid metabolism (15, 27–29). Some metabolic signatures reported in ME/CFS appear to 
be common in other chronic diseases, whereas others seem more specific. For example, the reduced levels 
of  branched chain amino acids (BCAAs) reported in patients with ME/CFS (15, 26, 28) are contrary to the 
increased levels generally related to inactivity, obesity, and insulin resistance (30–32).
Metabolism plays a central role in inherent physiological programs that evolved to protect against defi-
ciencies and threats, such as starvation, hypoxia, and infection (33, 34). These programs also involve immune 
and inflammatory processes and overlap with mechanisms supporting energetics, performance, and recovery 
in the context of  physical activity and restitution (35, 36). Corrupted or untimely immunometabolic interac-
tions are important in chronic diseases such as diabetes, multiple sclerosis, and rheumatoid arthritis (34, 37, 
38). Furthermore, energy metabolism is directly linked to mechanistic elements that may contribute to fatigue, 
such as depletion of  energy nutrients and oxygen (39, 40). Such effects compromise mitochondrial function, 
which has been proposed as a contributing factor in ME/CFS (41–43). We previously found indications that 
obstructed pyruvate flux through the central mitochondrial enzyme pyruvate dehydrogenase (PDH) plays a 
role in ME/CFS (15), and this is supported by other studies reporting changes in amino acid and TCA metab-
olites (27–29, 44). Despite these findings, we do not have a complete overview regarding changes in systemic 
energy metabolism in patients with ME/CFS.
The aim of the present study was to map metabolic phenotypes of  ME/CFS and thereby gain insights 
into disease-related mechanisms. We performed comprehensive serum metabolite measurements and explor-
atory data analyses (EDA), and we found both common and variable alterations in the ME/CFS patient 
group. The abnormalities covered recognizable patterns of  energy strain, as well as context-dependent signa-
tures of  deregulated metabolism. The possible clinical impact should be further investigated, as some aspects 
may contribute to worsening of  the disease.
Results
Cohort characteristics
Comprehensive investigation of serum metabolites was performed employing global metabolomics and lipid-
omics. Differences in metabolite profiles at group and subgroup levels were further investigated using clinical 
data, quantitative blood biochemistry measurements, and metabolic hormone analyses. The study included 35 
healthy controls (HC) and 83 patients with ME/CFS who were included in the rituximab (51 patients) or cyclo-
phosphamide (32 patients) intervention studies (12, 45). The HC and ME/CFS groups had a similar sex and 
age distribution (Table 1). The mean BMIs were comparable between the groups. There was a tendency toward 
more individuals with BMI > 25 among the patients with ME/CFS, but there was no statistical differences in 
the relative distribution in BMI categories. BMI data were missing for 5 of the HC subjects. All patients with 
ME/CFS had been sick for more than 2 years, and the disease severity ranged from mild to severe.
Global metabolomics
The global metabolomics analysis (HD4 platform, Metabolon Inc.) detected 880 serum compounds in the study 
cohort. Based on initial pilot statistical analyses, we designed a strategy for EDA aiming to unravel interesting 
patterns and generate hypotheses, as displayed in Figure 1. Throughout the study, statistical significance for each 
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metabolite was evaluated based on both univariate P value (2-tailed Welch’s test) and multivariate adjusted P val-
ue (Benjamini-Hochberg adjustment; q value). Since this was an exploratory study, univariate P < 0.05 was used 
as the standard criterion for significance. The different data elements of the analysis are provided as listed in Sup-
plemental Data Set 1, sheet 1 (supplemental material available online with this article; https://doi.org/10.1172/
jci.insight.149217DS1), and pathway abbreviations are defined in sheet 2 of the same file. After excluding com-
pounds with high levels of missing values, and xenobiotic molecules, the statistical analysis included 610 differ-
ent compounds (Supplemental Data Set 1, sheet 3). Using univariate statistical analysis, 159 of 610 metabolites 
were found to be significantly different between the ME/CFS and HC groups (2-tailed Welch’s test, P < 0.05; 
84 were q-significant), of which 87 of 159 had elevated and 72 of 159 had lower serum concentrations in the 
patients (Supplemental Data Set 1, sheet 4). The majority of affected metabolites were linked to lipid (75 of  
159) and amino acid (49 of 159) metabolism. Inside both the ME/CFS and HC groups, the data heterogeneity, 
expressed by the coefficient of variation (CV), differed between the individual metabolites (Figure 2, A and B). 
Although the heterogeneity profiles in the 2 groups mirrored each other, the ME/CFS group expressed overall 
higher internal variation compared with the HC group, which has also been observed in other cohorts (25). 
Theoretically, homogenous effects in the ME/CFS group may reflect common disease mechanisms, whereas 
heterogeneous traits more likely express context-dependent changes that may be influenced by multiple factors.
Table 1. Characteristics of patients with ME/CFS and healthy control subjects and explorative ME/CFS subsets
Characteristics Included subjectsA Explorative ME/CFS metabotypesB
HC ME/CFS ME-M1 ME-M2 ME-M3 ANOVA

























BMI (kg/m2) Mean ± SD 23.9 ± 2.4 24.4 ± 4.5 23.1 ± 4.0C 25.7 ± 5.0C 23.8 ± 2.8 0.0251







































































































































Means steps/24 hours Mean ± SD NA 2952 ± 1973 3218 ± 2173C 2274 ± 1461C,D 4225 ± 2079D 0.0093
SF-36-PF score Mean ± SD NA 29.3 ± 19.5 33.1 ± 20.8C 22.37 ± 16.0C,D 40.4 ± 19.4D 0.0078
Self-reported function (%) Mean ± SD NA 16.3 ± 8.0 18.1 ± 9.9c 13.9 ± 5.7C,D 18.6 ± 6.9D 0.0408
NA, not applicable; SF-36-PF, SF-36 physical function subscale. AStatistical comparison of ME/CFS versus HC. None of the parameters showed statistical 
significance; 2-tailed Welch’s t test on continuous data, and Fisher’s exact test on categorical data; P < 0.05. BStatistical comparison of the tree explorative 
ME/CFS metabotype subsets (ME-M1, ME-M2, ME-M3). Age and BMI were compared using 4-group (HC, ME-M1, ME-2, ME-3) 1-way Welch’s ANOVA test. 
Mean steps/24 hours, SF-36-PF score and self-reported function were compared between the 3 ME/CFS subsets using 1-way Welch’s ANOVA. Statistical 
significance is indicated with numbers in bold; P < 0.05. Categorical data were analyzed using multiple Fisher’s exact tests comparing each pair of groups 
but did not reveal significant differences. CP < 0.05, ME-M1 versus ME-M2, 2-tailed Welch’s test. DP < 0.05, ME-M2 versus ME-M3, 2-tailed Welch’s test.
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Multivariate analysis identified 3 different metabolic phenotypes (metabotypes) of ME/CFS
To detect possible subsets of  patients with ME/CFS with different metabolic profiles, we performed 
k-means clustering using the 159 metabolites that had statistically significant level differences (P < 0.05) 
between the ME/CFS and HC groups to generate a heatmap (Figure 2C). The majority of  the HC sub-
jects clustered together (33 of  35 subjects), whereas 84% of  the patients with ME/CFS (70 of  83 patients) 
clustered into 2 subgroups with clearly different metabolic phenotypes: metabotype 1 (ME-M1; 32 of  83 
patients) and metabotype 2 (ME-M2; 38 of  83 patients). The remaining small group of  patients with ME/
CFS (metabotype 3 [ME-M3]; 13 of  83 patients) clustered together with the HC subjects. One HC subject 
was present in each of  the ME-M1 and ME-M2 clusters. Since the ME-M1 and ME-M2 subsets represented 
the major and most distinct phenotypes of  this cohort, they attracted primary focus throughout the study.
Figure 1. Explorative data analysis (EDA) strategy. In data preprocessing, the raw peak data from the global metabolomics platform (Metabolon Inc., HD4) 
was preprocessed by first excluding variables with more than 25% missing values, metabolites classified as xenobiotics, and partially characterized molecules. 
Missing values were then imputed for the remaining variables. The variables were subsequently quantile normalized. In multivariate analysis, initial univariate 
analysis was performed on the raw normalized data using 2-tailed Welch’s test revealing 159 significant metabolites (based on P value). Fold change was also 
calculated. The normalized raw data were scaled using autoscaling before further multivariate analyses were performed. The 159 significant metabolites from 
the first univariate analyses were used for the multivariate analyses. The k-means clustering was used generate 3 patient subsets. Principal component anal-
ysis (PCA) was performed, and a loading plot was generated. The subsets discovered in the k-means clustering was used in the visualization of the PCA plot to 
display the variance observed between patient subsets. Additional metadata were implemented to investigate possible impacts of factors such as such as sex 
and fasting state. In univariate analysis, the HD4 data set was reanalyzed to separately compare the 3 ME/CFS metabolic subsets with the HC group using the 
HD4 data set. These data were used to create plots for visualization. The curated complex lipid data set (Metabolon Inc., CLP) was also analyzed according to 
the established ME/CFS subsets.
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As an additional and independent strategy to evaluate the different metabotypes, we performed principal 
component analysis (PCA) using the same 159 variables described above (Figure 3A). At a group level, the 
patients with ME/CFS showed considerably more scattered distribution in the PCA plot compared with the 
HC subjects, confirming the larger data variance. There was considerable overlap between the 2 groups in the 
PCA plot; however, when we annotated (using colored symbols) according to the subsets from the k-means 
clustering, it was evident that subjects of  the same metabotype grouped together. In the annotated plot, there 
was relatively little overlap between the HC, ME-M1, and ME-M2 clusters, whereas the ME-M3 subset posi-
tioned as a merger phenotype between the 3 others.
The 2 strategies of  multivariate analysis consistently supported the division of  the ME/CFS cohort into 
3 subsets based on serum metabotype and simultaneously uncovered specific metabolites that were differently 
affected between the subsets. Based on the clustering analysis, the metabolites divided into 3 groups (referred 
Figure 2. Clustering analysis of global metabolite data. Untargeted global metabolome analysis in serum from 35 healthy controls (HC) and 83 patients with 
ME/CFS (ME). Initial analyses identified 159 metabolites significantly different in patients with ME/CFS compared with the HC group (2-tailed Welch’s test, 
P < 0.05). (A) The graph illustrates the coefficient of variation (CV) for all the significantly altered metabolites. The metabolites are organized along the x axis 
according to their CV in the ME/CFS group, with increasing CV from left to right. (B) Linear regression of the data in A to assess the overall difference in data 
heterogeneity between the 2 groups. (C) Heatmap based on k-means clustering using the 159 significantly different metabolites. The heatmap shows the auto-
scaled levels of each metabolite in each sample, colored blue for decline and red for elevation as indicated on the vertical bar. The patients with ME/CFS clus-
tered into 3 subsets with different metabolic phenotypes, here referred to as metabotypes (M1–M3). The M1 and M2 subsets contained the majority of patients 
with ME/CFS, and only 1 HC subject clustered with each of them. The third cluster contained the majority of HC subjects and the remaining patients with ME/
CFS (M3; separated from HC with a gray line). The heatmap split the 159 metabolites into 3 blocks, or “signatures,” for which the involved metabolite classes are 
indicated (color-coded) underneath the heatmap. (D) “Tree map” illustrating the relative contributions (box sizes) of the metabolite classes in each metabolite 
block. The colors indicate the metabolite class, while the abbreviated subclasses are written inside the boxes (see Supplemental Data Set 1 for full names).
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to hereafter as metabolite blocks) with different discriminating impact on the metabotype (Supplemental Data 
Set 1, sheet 5). Figure 2D displays the types and relative abundance of  affected metabolites in the different 
metabolite blocks (abbreviations provided in Supplemental Data Set 1, sheet 2). Overall, the patterns that 
separated the ME/CFS subsets were dominated by lipid and amino acid metabolites. This notion was further 
supported by the PCA. Principal component 1 (PC1) and PC2 together explained 21.4% of the variation (PC1 
13.2 %, PC2 8.2%; Figure 3A) and were primarily driven by heterogeneity in lipid and amino acid metabolites 
(Figure 3B; the top 30 metabolites of  PC1 and PC2 are provided in Supplemental Data Set 1, sheet 6). The 
metabolic signatures of  the different metabotypes are described in more detail in the next sections.
Evaluation of the ME/CFS metabotype subsets
We evaluated possible confounding factors that could have influenced the ME/CFS metabotypes, such as sex, 
BMI, medication, and critical elements of the statistical analysis. An extensive summary of these investigations 
is provided in Supplemental Data 1, with complementary data in Supplemental Data Set 3 (impact of missing 
value imputation in different subsets [group, sex, metabotype]) and Supplemental Data Set 4 (separate univariate 
Figure 3. Validation of different metabotypes. Metabolomics in serum from 35 healthy controls (HC) and 83 patients with ME/CFS (ME) identified 159 
significantly different metabolites (2-tailed Welch’s test, P < 0.05). (A) Principal component analysis (PCA) plot based on the significantly different 
metabolites. The PCA was performed independently of the introductory k-means clustering analysis. However, the clusters from the k-means analysis 
(in Figure 2C) have been used as an overlay to evaluate the associations and robustness of the proposed ME/CFS subsets. The sex of each subject is also 
indicated (dots, female; triangles, male). (B) Loading plot showing the contributions of the 30 main metabolites of PC1 and PC2, color-coded according to 
the metabolite class. (C–E) Clinical laboratory measurements of serum glucose (C), serum triglycerides (s-TAG) (D), and serum nonesterified fatty acids 
(s-NEFA) (E). Data are presented as mean ± SD, and the reference range is shown with dotted lines. (F) Mean steps/24 hours. P values; 1-way Welch’s 
ANOVA test, comparison of M1, M2, and M3. *P < 0.05; ****P < 0.00001; 2-tailed Welch’s test.
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analysis in female and male patients). The metabotypes did not associate with sex, and they were adequately 
expressed in both sexes. Although BMI showed some influence, the possible impact of obesity appeared weak 
as the metabotypes were adequately reproduced in nonobese subjects (BMI < 25). Furthermore, we did not find 
significant influences of age or postprandial fasting time. Based on the 185 xenobiotic molecules excluded from 
the multivariate clustering analysis, we found no association between metabotype and specific drugs or dietary 
products (Supplemental Data Set 1, sheet 11). However, as expected patients with ME/CFS generally had 
overall higher levels of metabolites of supportive drugs relative to the HC group; for instance, they had higher 
levels of nonsteroid antiinflammatory drugs (NSAIDs). To summarize, the control investigations did not reveal 
interactions indicating that the external factors were responsible for the multivariate clustering pattern.
Clinical laboratory data on blood biochemistry were available for most of the included patients with ME/
CFS (Table 2; data according to sex in Supplemental Data 2). Although the clinical laboratory results were 
mainly within normal ranges, the ME/CFS metabotype subsets presented different serum lipid profiles. Blood 
glucose levels were similar between the ME/CFS subsets (Figure 3C). The ME-M1 subset was particularly char-
acterized by high nonesterified fatty acid (NEFA) level and ME-M2 by high triglyceride (TAG) and low NEFA 
levels (Figure 3, D and E). These different blood lipid profiles support the notion that the uncovered ME/CFS 
metabotypes represent subclinical metabolic changes maintained by the underlying chronic pathology.
The overall mean BMI was similar between the ME/CFS and HC groups (24.4 ± 4.5 kg/m2 versus 23.9 
± 2.4 kg/m2, respectively; Table 1). The ME-M1 subset had lower mean BMI compared with the ME-M2 
subset (23.1 ± 4.0 kg/m2 versus 25.7 ± 5.0 kg/m2, P < 0.05), but none were significantly different from the 
HC group. The ME-M2 group had a proportionally larger fraction of  individuals with BMI > 25 compared 
with the HC group (55.3% versus 23.4%; Fisher’s exact test, P < 0.05).
Regarding severity, the cumulative proportion of patients in the 2 most severe categories (moderate/severe 
and severe ME/CFS) tended to be larger in the ME-M2 subset compared with the 2 other subsets, but the dif-
ference was not statistically significant (Table 1). In the ME-M3 group, the majority of patients (11 of 13) were 
diagnosed with mild/moderate or moderate severity, but the number of patients in this group was too low to 
make firm conclusions. However, there were significant differences between the subsets in the physical function 
scores (mean steps per 24 hours, Short form-36 Health Survey, Physical Function subscale [SF-36-PF] and 
self-reported function level in percent; Table 1 and Figure 3F). Based on an overall assessment, the apparent 
function levels were ranked in the following order: ME-M2 < ME-M1 < ME-M3. The ME-M2 patients had a 
mean SF-36-PF score as low as 22.2 ± 16.0.
Supported by available patient characteristics and clinical laboratory data, we concluded that the ME/
CFS metabotypes discovered through global metabolomics represent 3 adequate subsets of  patients with 
discernable and physiologically relevant differences in blood biochemistry and clinical profile.
Table 2. Clinical blood biochemistry data for the patients with ME/CFS
ME/CFS ME-M1 ME-M2 ME-M3
Unit Mean ± SD N Mean ± SD N Mean ± SD N Mean ± SD N ANOVA
Hemoglobin g/dL 14.18 ± 1.23 54 14.34 ± 1.32 23 13.98 ± 1.20 21 14.26 ± 1.12 10 0.62
Albumin g/L 46.04 ± 3.16 69 47.37 ± 2.99A 27 45.03 ± 3.27A 32 45.7 ± 2.00 10 0.023
Folate nmol/L 20.73 ± 10.08 77 24.38 ± 11.15A 28 17.50 ± 8.96A 37 22.15 ± 8.02 12 0.03
Glucose mmol/L 5.24 ± 0.85 71 5.23 ± 0.74 28 5.18 ± 0.95 32 5.42 ± 0.87 11 0.75
Cholesterol mmol/L 5.01 ± 0.95 78 4.84 ± 0.98 30 5 ± 0.88 37 5.53 ± 0.97 11 0.15
HDL mmol/L 1.44 ± 0.35 78 1.52 ± 0.37 30 1.37 ± 0.35 37 1.46 ± 0.30 11 0.27
LDL mmol/L 3.27 ± 0.91 63 3.17 ± 0.93B 25 3.14 ± 0.77C 29 3.98 ± 1.05B,C 9 0.11
TAG mmol/L 1.40 ± 0.87 48 1.06 ± 0.45A 15 1.65 ± 1.03A 28 1.04 ± 0.23 5 0.0351
NEFA mmol/L 0.38 ± 0.29 75 0.65 ± 0.27A,B 27 0.21 ± 0.16A 36 0.27 ± 0.16B 12 <0.001
TSH mIU/L 2.14 ± 1.09 66 1.98 ± 1.18 26 2.27 ± 1.14 29 2.18 ± 0.72 11 0.64
Free T4 pmol/L 16.61 ± 2.15 65 16.29 ± 2.37 26 16.9 ± 2.07 28 16.65 ± 1.83 11 0.87
ACTH pmol/L 4.77 ± 2.89 66 4.20 ± 2.48 26 5.24 ± 2.76 29 4.86 ± 4.02 11 0.36
Cortisol 
(morning) nmol/L 408.3 ± 251.7 66 301.8 ± 127.7
A 26 505.5 ± 317.6A 29 404.2 ± 178 11 0.009
Three-group comparison of the metabotype subsets was done using 1-way Welch’s ANOVA test. Two-group comparisons: AP < 0.05, ME-M1 versus ME-M2, 
2-tailed Welch’s test. BP < 0.05, ME-M1 versus ME-M3, 2-tailed Welch’s test. CP < 0.05, ME-M2 versus ME-M3, 2-tailed Welch’s test.  
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Metabolic characteristics of ME/CFS
Since the initial establishment of  the 3 ME/CFS metabotype subsets was based only on the 159 distinguishing 
metabolites from the univariate analyses, the entire data set was reanalyzed to explore contextual metabo-
type-specific changes in all the 610 metabolites (Figure 4). The metabolites were annotated to compound class 
as provided in Supplemental Data Set 1 (sheet 3). When compared with the HC group, the number of  affected 
metabolites (P < 0.05) were 272 in the ME-M1 subset, 216 in the ME-M2 subset, and 46 in the ME-M3 subset. 
The higher numbers of  affected metabolites in the subsets relative to the entire ME/CFS group are largely 
explained by the more homogenous metabolome within the subsets. Thus, the greater data variance for some 
metabolites in the total ME/CFS group relative to the HC group can be ascribed to differences between the 
metabotype subsets. The subsets showed characteristic patterns with respect to lipid and amino acid metab-
olites (Figure 4A). Substantial differences between the ME/CFS subsets became evident when viewing the 
data per metabolite subclass (Figure 4B). In Figure 5, we have extracted key parameters signaling recogniz-
able shifts in energy metabolism, as implemented in the following sections.
In order to cluster processes that may be mechanistically or functionally connected, we evaluated com-
mon and specific features in the ME-M1 and ME-M2 subsets. A proportion of  the metabolites were uniform-
ly affected in the 2 subsets (67 of  610; Supplemental Data Set 1, sheet 7) — i.e., they were either high or low in 
both subsets compared the HC group. These uniform effects may theoretically be associated with a common 
pathomechanism, as described in further detail below. In contrast, some metabolites displayed different or 
even opposing effects in the ME-M1 and ME-M2 subsets; consequently, this reduced or completely neutral-
ized the overall effects in the total ME/CFS group. Such metabotype-specific effects were particularly evident 
for some lipid and amino acid molecule classes (e.g., monounsaturated long-chain fatty acids), and possibly 
represent different context-dependent consequences of  the underlying pathology.
Uniform metabolic effects in the ME/CFS group. Of the 610 measured metabolites, 34 were lowered and 33 
were elevated in both the ME-M1 and ME-M2 subsets relative to the HC group (Supplemental Data Set 1, 
sheet 7). Certain amino acid pathways were prominent among the uniformly affected metabolites. Several 
derivatives of  BCAAs (such as isovalerylglycine) were reduced in both the ME-M1 and ME-M2 subsets (Fig-
ure 5H), and these are particularly linked to muscle energy metabolism. Specific tryptophan metabolites were 
either elevated or reduced in both ME/CFS subsets, possibly suggesting changes in the kynurenine pathway 
and NAD biosynthesis. Reduced serum kynurenate concentration was a consistent effect in all 3 subsets (Fig-
ure 5E). Also, several tyrosine metabolites were uniformly affected, including slightly elevated thyroxine level. 
Three metabolites of  lysine were uniformly elevated in both the ME-M1 and ME-M2 subsets. These effects 
were accompanied by elevated levels of  glycerol (Figure 5D) and short-chain acylcarnitines (butyrylcarnitine, 
S-3-hydroxybutyrylcarnitine), which are features known to associate with a lipolytic and ketogenic metabolic 
state (46). In summary, these common effects in the ME-M1 and ME-M2 subsets appear compatible with 
altered utilization of  fatty acids and amino acids for energy fueling, as previously suggested (15), yet with con-
textual effects on adjacent pathways affecting the levels and transport of  respective substrates and products. 
In agreement with a state of  energy strain, there were uniform increments in several nucleotide degradation 
products such as adenosine and xanthosine (Figure 5F and Supplemental Data Set 1, sheet 7), which also 
could be consistent with alterations in amino acid metabolism (36, 47). In addition, the serum concentrations 
of  2 arachidonic acid derivatives, 12-hydroxyeicosatetraenoic acid (12-HETE) and 12-hydroxyheptadecatre-
noic acid (12-HHTrE), were uniformly lowered in the ME/CFS subsets. There were slightly lower levels of  
some metabolites of  vitamin A, B3, and C in both the ME-M1 and ME-M2 subsets, and there were also lower 
levels of  metabolites of  choline, which is considered an essential vitamin. Finally, some metabolites associat-
ed with corticosteroids, fibrinopeptide A and B fragments, and collagen were elevated in both subsets.
Metabotype ME-M1. This subset (n = 32) had significantly elevated levels of 134 of 610 metabolites and low-
ered levels of 138 of 610 metabolites, compared with the HC group (Supplemental Data Set 1, sheet 8). A strik-
ing feature in these patients were the elevated concentrations of ketone bodies (3-hydroxybutyrate [i.e., β-hy-
droxybutyrate] and acetoacetate; Figure 5G), which could indicate a shift toward a more ketogenic metabolic 
state also involving increased fatty acid oxidation. This is coherent with increased lipolysis, as indicated by the 
elevated glycerol level, which was a uniform effect in the total ME/CFS group (Figure 5D). In the ME-M1 sub-
set, there was a particularly high number of circulating lipid molecules displaying increased levels compared 
with the HC group (Figure 4A). These were primarily derivatives of fatty acids, with different chain length, 
saturation level, and adducts (Figure 4B). In agreement with clinical laboratory results, there was elevation in 
serum NEFAs in the ME-M1 subset (Figure 5A), and this was accompanied by increased concentration of  
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Figure 4. Overview of metabolite classes. The serum metabolite data set was reanalyzed to overall compare the ME/CFS group (ME/ALL) and the metabotype 
subsets (M1–M3) relative to the HC group. (A) The volcano plots give a general overview of all metabolites in a given class, with the –log10 of the P value on the 
y axis and log2 fold change on the x axis. Each dot represents a metabolite and is colored according to direction of change and significance level relative to HC as 
indicated (P < 0.05, 2-tailed Welch’s test; q < 0.05, adjusted P value). The number in each quadrant provides the respective counts of q-significant metabolites, 
and additional P-significant metabolites are shown in parentheses. (B) The tile plots display single metabolite changes according to metabolite class. Each tile 
represents a metabolite and is colored according to direction of change and significance level, for the entire ME/CFS group (ME/ALL) and the subsets (M1–M3) 
relative to HC as indicated (P < 0.05, 2-tailed Welch’s test; q < 0.05, adjusted P value).
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acylcarnitines (Figure 5B). Elevated total NEFA concentration was found in both women and men in this sub-
set (Supplemental Data 2). Lipid compounds that tended to show decreased serum levels in ME-M1 patients 
included metabolites of acylcholines, phospholipids and lysophospholipids, bile products, and sterols (Figure 
4B). Serum glucose was slightly elevated in the ME/CFS group compared with the HC group, but it was not 
significantly elevated in the ME-M1 subset. The clinical laboratory results showed similar mean blood glucose 
concentrations in the patient subsets (Figure 3 and Table 2). Moreover, this metabotype was characterized by 
low levels of many amino acid metabolites compared with HC subjects (Figure 4A), including metabolites of  
tryptophan, the BCAAs (leucin/isoleucine/valine), arginine/proline, and phenylalanine (Figure 4B). This was 
also accompanied by low circulating levels of multiple di- and oligopeptides. However, affected lysine metabo-
lites were generally increased in this subset. Minor effects were found for pyruvate (Figure 5C) and TCA cycle 
metabolites. In conclusion, the ME-M1 metabotype appears to reflect a lipolytic state with increased utilization 
of both fatty acids and amino acids as energy substrates, possibly due to ineffective carbohydrate catabolism.
Metabotype ME-M2. This subset (n = 38) displayed significantly elevated levels of  119 of  610 metabolites 
and lowered levels of  97 of  610 metabolites (Supplemental Data Set 1, sheet 9). The ME-M2 patients had pre-
dominantly lower serum levels of  fatty acid derivatives (Figure 4B). However, mobilization of  fatty acids from 
Figure 5. Key characteristics of ME/CFS metabotypes. Key serum molecules were investigated to evaluate contextual changes in systemic energy 
metabolism. (A and B) Nonesterified saturated fatty acids (A) and saturated acylcarnitines (B) in the ME/CFS group (ME) and subsets (M1-M3), calculated 
relative to the HC group. The fatty acid chain length is denoted on the x axis (Carbons#). (C–H) Serum levels of pyruvate (glucose metabolite) (C), glycerol 
(product of lipolysis) (D), kynurenate (Trp metabolite) (E), xanthosine (purine metabolite) (F), 3-hydroxybutyrate (β-hydroxybutyrate; ketone body) (G), and 
isovalerylglycine (BCAA product) (H). The metabolite levels are displayed as log2 transformed normalized compound peak values. Data are presented as 
mean ± SD. *P < 0.05, 2-tailed Welch’s test; **q <0.05, adjusted P value.
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stored lipids appeared to occur as the concentration of  glycerol, a product of  TAG lipolysis (48), was elevated, 
as also seen in the other 2 ME/CFS subsets (Figure 5D). In agreement with the clinical blood tests (Figure 
3C), serum glucose was found normal in the ME-M2, but there was enrichment of  other carbohydrates — in 
particular, sucrose. There was a significant increase in serum pyruvate in the ME-M2 subset (Figure 5C), 
possibly due to reduced mitochondrial pyruvate oxidation (15). Affected amino acid metabolites linked to 
pathways of  alanine/aspartate/asparagine, methionine/cysteine/taurine, lysine, glutamate/glutamine, his-
tidine, and phenylalanine, generally expressed higher levels than in the HC group (Figure 4B). For affected 
metabolites of  tryptophan, BCAAs, glycine/serine/threonine/creatine, tyrosine and arginine/proline, there 
were both reduced and increased levels in this patient subset. Notably, the serum tryptophan concentration 
was elevated in the ME-M2 subset, in contrast to the reduced level in the ME-M1 subset, yet both expressed 
a decline in certain downstream intermediates, such as kynurenate (Figure 5E). Furthermore, the elevated 
concentration of  bile products was specific for this subset, as were high levels of  certain γ-glutamyl dipeptides 
(gGlu-AAs; Figure 4B). In conclusion, the ME-M2 metabotype shows indications of  disrupted control of  
lipid metabolism, possibly involving compromised activity of  mitochondrial oxidation pathways and conse-
quent effects on lipid trafficking and storage.
Metabotype ME-M3. This subset (n = 13) had relatively few features that were significantly different from 
the HC group. Only 21 of  610 metabolites showed reduced levels, whereas 25 of  610 metabolites showed 
increased levels (Figure 4; Supplemental Data Set 1, sheet 10). This was expected, since there were relatively 
few of  these patients and they were partly clustered together with HC subjects in the multivariate analyses. 
The ME-M3 subset was found to reflect an intermediate state between the 2 other ME/CFS metabotypes, 
albeit with some more similarity with the ME-M2 phenotype.
The lipidomes of ME/CFS
Comprehensive analysis of  complex lipids was performed in serum from the same study cohort. Of  the 
included 892 lipid species, 153 presented significantly different serum concentrations in the ME/CFS 
group relative to the HC group, of  which 34 had lower level and 119 had higher level (Figure 6A; Supple-
mental Data Set 2, sheets 2 and 4). The lipid class sum concentrations indicated elevation of  diacylglycerols 
(DAG), TAG, and dihydroceramides (DCER) and reduction of  lysophosphatidylcholines (LPC) in the 
ME/CFS group compared with the HC group (Supplemental Data Set 2, sheet 3). However, distinct dif-
ferences in lipid profile were evident when subgrouping according to the proposed ME/CFS metabotypes. 
Overall, there was extensive coherence between lipid-related effects observed on the global metabolomics 
(HD4) and lipidomics (complex lipidomics platform [CLP]) platforms. The following is a summary of  the 
uniform and metabotype-specific changes in serum lipids in patients with ME/CFS relative to HC subjects.
Uniform lipidome effects in the ME/CFS group. Only 16 of  the 892 lipid species presented uniform effects 
in the ME-M1 and ME-M2 subsets relative to the HC group (Supplemental Data Set 2, sheet 5). Of  these, 
13 compounds had lower serum concentration in ME/CFS patients, and all these were phospholipid deriv-
atives of  phosphatidylcholine (PC) and phosphatidylethanolamine (PE), including LPC and lysophospha-
tidylethanolamine (LPE). This included several PE plasmalogen compounds, which represent a chemically 
and biologically unique phospholipid subclass (49). Ten of  the 13 uniformly lowered phospholipid species 
contained at least one 18:2 acyl moiety, which represents linoleic acid, an essential fatty acid and arachidon-
ic acid (20:4) precursor. Overall, the level of  linoleic acid tended to be low in the phospholipid subclasses 
(PC, PE, phosphatidylinositol [PI], LPC, and LPE; Figure 6B). Only 3 single lipid species were uniformly 
elevated — the sphingolipids, CER(18:1), SM(18:0), and SM(18:1) — yet additional sphingolipids showed 
similar trends. Regarding effects on total serum fatty acid content (i.e., esterified and nonesterified), the 
only significant uniform change in the ME-M1 and ME-M2 subsets was reduced level of  14:0 (Figure 6B).
Metabotype ME-M1 lipidome. This subset had significantly elevated serum concentration of  23 of  892 
and lowered level of  227 of  892 lipid metabolites compared with the HC group (Figure 6; Supplemental 
Data Set 2, sheet 6). Most of  the elevated metabolites were NEFAs (18 of  the 25 measured free fatty acids; 
Figure 6A), contributing to the higher total NEFA concentration. The remaining 5 elevated compounds in 
the ME-M1 subset were all sphingolipids containing 18:0 or 18:1 (CER[18:0], CER[18:1], DCER[18:0], 
SM[18:0], SM[18:1]). The 227 lowered metabolites predominantly included species of  glycerolipids (138 
TAG, 5 DAG, 2 monoacylglycerols [MAG]) and phospholipids (79, including 16 lysophospholipids), 
in addition to SM(14:1), SM(22;1), and CE(14:1). Although the sum concentration of  TAG was not signifi-
cantly lowered relative to the HC group, the lowered levels of  multiple single TAG are coherent with the 
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relatively low total serum TAG concentration observed in laboratory measurements (Figure 3D). Further-
more, there was significant or trending decrease in the sum concentrations of  phospholipids (PC, PI, trend 
for PE) and lysophospholipids (LPC, LPE) (Supplemental Data Set 2, sheet 3). There was no significant 
effect on total levels of  sphingolipid subclasses, but there was a trend for lower total DCER level. In the 
NEFA fraction, there was a particular relative enrichment (mole percent) of  the 16:1, 18:1, and 18:2 fatty 
acids, whereas the TAG fraction had significantly lower content of  C12 and C14 fatty acids (Supplemen-
tal Data Set 2, sheet 10). The findings are compatible with increased mobilization and oxidation of  fatty 
acids, as suggested by increased concentrations of  free fatty acids, glycerol, and ketone bodies. The observed 
changes in the ME-M1 subset may mimic metabolic adaptations known to occur in response to energy 
Figure 6. Overview of lipid classes. The serum lipidome data set was analyzed to overall compare the ME/CFS group (ME/All) and the 3 metabotype subsets 
(M1–M3) relative to the HC group. (A) The volcano plots give a general overview of all lipid molecules in a given class, with the –log10 of the P value on the y 
axis and log2 fold change on the x axis. Each dot represents a metabolite and is colored according to direction of change and significance level relative to HC as 
indicated (P < 0.05, 2-tailed Welch’s test; q < 0.05, adjusted P value). The number in each quadrant provides the respective counts of q-significant metabo-
lites, and additional p-significant metabolites are shown in parentheses. (B) The relative amount of specific fatty acids (FA, first column) in the different lipid 
classes (column title) in the total ME/CFS group (bottom label, A) and according to metabotype subsets (M1–M3). The color of the heatmap cells display the 
log2 fold change relative to HC, as indicated. *P < 0.05, 2-tailed Welch’s test; **q < 0.05, adjusted P value. Total, total sum of fatty acids across all lipid classes; 
CE, cholesterol ester; CER, ceramide; DAG, diacylglycerol; DCER, dihydroceramide; FFA, free fatty acid (synonymous to nonesterified fatty acid, NEFA); HCER, 
hexosylceramide; LCER, lactosylceramide; LPC, lysophosphatidylcholine; LPE, lysophosphatidylethanolamine; LPL, lysophospholipid; MAG, monoacylglycerol; 
PC, phosphatidylcholine; PE, phosphatidylethanolamine; PI, phosphatidylinositol; PL, phospholipids, SM, sphingomyelin; SP, sphingolipids; TAG, triacylglycerol.
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strain triggered by starvation or exercise (50, 51). Theoretically, such a response could be caused by aberrant 
regulation of  glucose catabolism, a chronic high ATP demand, or uncoupling of  mitochondrial respiration 
leading to excessive oxidative flux and inefficient ATP production.
Metabotype ME-M2 lipidome. This subset had higher concentrations of 538 of 892 lipid compounds, and 
lower concentrations of 27 of 892, compared with the HC group (Figure 6; Supplemental Data Set 2, sheet 
7). The vast majority of the elevated compounds were different species of either TAG (454 species) or DAG 
(43 species; Figure 6); accordingly, there were significantly higher total serum concentrations of these 2 lipid 
classes. There were also higher levels of some single species — and the total class concentration — of choles-
terol esters. Multiple single phospholipids (25 species of PC, PE, and PI) and sphingolipids (8 species of SM, 
CER, DCER, and HCER) were elevated, but the total concentrations of these compound classes were mainly 
unaffected, apart from the PI class presenting significant increase compared with the HC group (Supplemental 
Data Set 2, sheet 3). Similar to the ME-M1 subset, there was no significant effect on total levels of sphin-
golipid subclasses. Several single NEFAs (10 species) had lower serum concentrations in the ME-M2 subset 
compared with the HC group, contributing to the lower total NEFA level. Regarding phospholipids presenting 
lower levels, the effects were essentially coherent with the changes already described as uniform in the ME/
CFS group. The elevated serum TAG concentration and lowered NEFA concentration in the ME-M2 subset 
compared with the HC group were confirmed in supplementary laboratory analyses (Table 2 and Figure 3D). 
In agreement with the higher TAG and DAG levels, there was a general increment in fatty acids esterified in 
these glycerolipids, across the fatty acid spectrum (Figure 6B). In summary, the metabolic phenotype of this 
subset was particularly characterized by a high serum concentration of TAG (women) and low NEFA (both 
sexes). Increased trafficking of TAG and DAG in blood is often associated with metabolic imbalance, excessive 
peripheral lipid accumulation, and induction of cellular and mitochondrial stress responses. Such effects have 
been described as consequences of various chronic diseases, also involving contexts of inflammation (34).
Metabotype ME-M3 lipidome. This small subset had higher concentrations of  22 of  892 lipids, and low-
er concentrations of  5 of  892 lipids, compared with the HC group (Figure 6A; Supplemental Data Set 
2, sheet 8). Elevation was primarily seen for certain cholesterol esters (7 species) and phospholipids (12 
species). Notably, the serum level of  6 PE plasmalogens was higher in this subset, which contrasted the 
effects on this phospholipid subclass in the 2 other ME/CFS subsets. The few lipids presenting lower serum 
concentration in the ME-M3 subset compared with the HC group included 2 NEFA species (FFA[14:0], 
FFA[20:4]) and 3 PC derivatives (LPC[20:2], PC[16:0/22:4], PC[18:1/20:2]). This subset displayed higher 
total SM level, and trends of  higher total cholesterol ester and PE levels, compared with the HC group. 
Relatively few effects were found regarding fatty acid composition of  the different lipid classes (Figure 6B). 
It appeared that several of  the affected single traits were unique to this subset compared with the others, 
but the possible implications are difficult to evaluate due to the low number of  subjects. Viewing the overall 
tendencies, the ME-M3 subset appeared to be more similar to the ME-M2 subset than the ME-M1 subset, 
as indicated by a trending elevation of  TAG.
Hormone signatures of metabolic stress
We investigated the circulating levels of  selected hormones controlling energy homeostasis in contexts of  
physiological strain, inflammation, and pathogenesis (Figure 7). Compared with the HC group, the ME/
CFS group had slightly elevated mean insulin and leptin serum levels, as well as lower high molecular weight 
(HMW) adiponectin (Figure 7, A–C). However, this was primarily driven by the ME-M2 subset, as no signif-
icant or trending effect was seen for the others. Accordant with increased insulin, the ME-M2 subset also had 
elevated mean concentration of  C-peptide (Figure 7D). These specific effects on hormone levels support dif-
ferent regulatory contexts in the ME-M1 and ME-M2 subsets, and the findings are coherent with the observed 
metabolic phenotypes indicating reduced glucose utilization (ME-M1) and excessive lipid accumulation (ME-
M2). Furthermore, there were increased serum concentrations of  FABP4 and FGF21 in the ME/CFS group 
compared with the HC group (Figure 7, E and F). These factors are regarded as signals of  energy strain and 
have been linked to metabolic disease as well as exercise (52, 53). Only the ME-M2 subset presented signifi-
cant elevation of  FGF21. There was a small group of  patients with a particularly high level of  FGF21 in the 
ME-M2 subset, and we suspect this may indicate an excessive burden of  hepatic metabolic stress. The eleva-
tion in serum FABP4 concentration was similar in the ME-M1 and ME-M2 subsets. The observed endocrine 
signatures are consistent with deregulated metabolism and elevated energy strain in patients with ME/CFS, 
and with links to regulatory networks that may explain context-dependent responses.
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Discussion
This exploratory metabolomics study revealed a map of common and variable metabolic phenotypes of ME/
CFS. The observed metabolic changes mainly fit into the paradigm of direct and indirect effects of energy 
strain. The physiological relevance was supported by associations with endocrine and clinical characteristics. 
Trough the following discussion, we suggest that energy strain may result from exertion-sensitive tissue hypoxia 
and leads to the systemic patterns of metabolic adaptation and compensation.
The common metabolic changes in the ME/CFS group were dominated by a relatively small number of  
pathways with credible impact on energy homeostasis. Elevated circulating glycerol suggests that lipolysis is 
induced, and this is normally observed during fasting and exercise (35, 48). In addition, several of  the find-
ings agree with altered utilization of  amino acids in patients with ME/CFS, including BCAAs, tryptophan, 
and others. The increase in breakdown products of  purine nucleotides such as adenosine and xanthosine 
also appeared as a possible signature of  energy strain, which normally reflects increased ATP demands and 
altered amino acid metabolism in muscle (36). Systemic metabolic stress was supported by elevated FABP4 
and FGF21, which may signal compensatory programs, as well as tissue specific responses (54, 55). Cortico-
steroids did not seem to be involved, since they depended on age and BMI instead of  physical function scores 
(Supplemental Data 3) and we did not find changes in morning cortisol and ACTH in ME/CFS compared 
with HC. There was a particular loss of  some phospholipids containing linoleic acid (18:2). This fatty acid is 
an essential precursor for arachidonic acid, a central messenger molecule linked to inflammation and vaso-
dilatation. The lowering of  arachidonic acid derivatives such as 12-HETE and 12-HHTrE further indicate 
that auto- and paracrine processes may be affected. As further discussed below, some of  these effects may be 
associated with mechanisms likely to be involved in symptoms of  ME/CFS.
The effects that were heterogeneous in the ME/CFS group expressed specific phenotypes of deregulated 
energy metabolism in subsets of patients. The 2 most distinct ME/CFS metabotypes, ME-M1 and ME-M2, 
aligned with well-known phenotypes of chronic diseases with immuno-metabolic projections (34, 37, 38). It 
should be kept in mind that none of the patients of our study had a clinical prediabetic or diabetic diagnosis. The 
ME-M1 subset presented elevated serum levels of free fatty acids (i.e., NEFA) and ketone bodies, despite normal 
glucose and insulin. This may resemble a context with physiological correlations to glucose starvation and exer-
cise (33, 35). In the ME-M2 subset, a different metabolic profile was expressed by the elevated serum TAG and 
insulin mean levels, yet blood glucose was not affected. This may reflect low-grade signs of lipid-induced insu-
lin resistance associated with ectopic peripheral lipid accumulation and inflammatory responses (56). Both the 
Figure 7. Changes in serum signaling factors linked to energy metabolism. Selected hormones potentially associated with energy strain and deregulated 
metabolism were measured in serum from patients with ME/CFS and HC subjects using immune-based methods. (A–F) The serum concentration was 
measured in 83 patients with ME/CFS and 30 HC subjects for insulin (pg/mL) (A), leptin (ng/mL) (B), HMW adiponectin (μg/mL) (C), C-peptide (pM) (D), 
FGF-21 (pg/mL) (E), and FABP4 (ng/mL) (F). The group median ± IQR is indicated. The shown P values (upper right) are for 4-group comparison of HC, M1, 
M2, and M3 using 1-way Kruskal-Wallis ANOVA. *P <0.05, Mann-Whitney U test; **q < 0.05, adjusted P value.
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ME-M1 and ME-M2 subsets convincingly expressed contexts of underlying energy strain, as further supported 
by the elevation of metabolic stress hormones such as FGF21 and FABP4. Furthermore, we have previously 
suggested that impaired function of PDH may play a role in ME/CFS (15), which is regarded as a common 
physiological response under energy strain (57, 58). The third and minor ME/CFS subset (ME-M3) clustered 
together with HC, albeit with some overlap with the other 2 subsets. The 3 ME/CFS metabotypes likely reflect 
compatible and functionally connected contexts of compensatory adaptations that may develop in a person-spe-
cific manner. Notably, the physical function scores ranked the subsets as ME-M2 < ME-M1 < ME-M3, and 
there were corresponding trending differences in disease severity. Therefore, it seems possible that these metabol-
ic contexts may influence, or be influenced by, the pattern and severity of symptoms.
Does the metabolic phenotype of ME/CFS resemble a state of elevated energetic strain? The circulat-
ing levels of amino acids may give useful information, since they are tightly linked to energy metabolism 
(59). A situation of energy strain, such as physical exercise, causes increased consumption of amino acids 
for energy purposes. Several studies, including the present, have found significant or trending reductions of  
energy-linked amino acids and their metabolites in blood and/or urine of patients with ME/CFS, such as seen 
for the BCAAs (15, 25, 27, 28, 44). Oxidation rates of BCAAs in muscle increase gradually during prolonged 
exercise, leading to glycogen depletion (60), which represents a well-known fatigue mechanism (39, 40, 61, 62). 
Amino acids also play important metabolic roles as TCA cycle anaplerotic precursors and gluconeogenetic 
substrates, both during exercise and recovery. The available findings in patients with ME/CFS show several 
similarities with recent data on the orchestrated choreography of biological processes during and after exercise 
(63). Such processes include the coordinated increase in rates of glycolysis, fatty acid oxidation, BCAA con-
sumption, and adenine nucleotide catabolism during exercise in healthy individuals. The decline in circulating 
BCAAs continued during recovery, in contrast to the effects on glucose and fatty acids, which nearly normal-
ized within 1 hour after the exercise. In addition to energy metabolism, multiple processes of inflammation, 
oxidative stress, and immune response were induced by exercise. Furthermore, the uniform elevation of purine 
nucleotide metabolites are of interest in this context, as AMP is an ammonia donor in muscle and normally 
net breakdown only occurs during conditions of working muscle such as exercise (36). These observations may 
suggest that metabolism is stressed in ME/CFS patients even in absence of activity. Our findings in ME/CFS 
ME-M1 patients showed some similarity with effects 14 hours after 3-day intensified exercise (64), including 
elevated free fatty acids, reduced bile products, and reduced BCAA metabolites. A chronic state of energy 
strain leading to persistent exercise metabolism would be expected to cause deficient capacity to accommodate 
additional energy demands. Such a mechanism appears relevant in ME/CFS and may theoretically contribute 
to key symptoms, such as fatigability and exertion intolerance.
The observed metabolic effects may be associated with tissue hypoxia caused by an underlying pathology 
related to an autoimmune mechanism (13). An autoantibody-mediated mechanism may influence, indirectly or 
directly, the fine-tuned autoregulation of blood flow required to meet the metabolic demands of tissues. Endo-
thelial dysfunction has been shown in patients with ME/CFS (65, 66), and this was also supported in substudies 
linked to the CycloME and RituxME trials (67). The reduced levels of certain arachidonic acid derivatives seen 
in the present study may impact the vascular tone and blood flow (68). Furthermore, abnormal RBC deforma-
bility has been reported in ME/CFS, which may affect their transport through capillaries (69). These findings 
pointing to vascular dysfunction support that exertion-triggered tissue oxygenation may be impaired, and clearly 
this would contribute to lowered activity tolerance and involve mitochondrial energy metabolism. One may also 
speculate that symptom-generating mitochondrial effects are pathologically reinforced by exertion, as observed 
after excessive exercise (70). Limited, and possibly local, tissue hypoxia and lactate accumulation may also be 
associated with chronic inflammation (71, 72). Oxygen restriction increases the demand for TCA anaplerosis 
(73), which also seems to be important in ME/CFS (15). At the group level, the patients with ME/CFS in the 
present study displayed normal resting lactate level, suggesting that tissue hypoxia is not a dominant factor in 
an unprovoked context. In fact, when we grouped the patients according to metabotype, the ME-M1 subset 
showed slightly lower — and the ME-M2 subset slightly higher — lactate concentrations compared with the 
HC group. We suspect this difference in resting serum lactate between the metabotype subsets to be linked to 
the corresponding trends for the precursor pyruvate, rather than differences in tissue oxygenation. However, the 
homogenous elevation of purine nucleotide metabolites that we observed in the ME/CFS group supports that 
oxygen supply may be a common limiting factor (74, 75). Exercise studies have indicated that low oxygen uptake 
by muscle cells, and insufficient metabolic adaptations to incremental exercise, are linked to exertion intoler-
ance in patients with ME/CFS (75–78). Reduced tissue perfusion through dysautonomia and/or inadequate 
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autoregulation of blood flow have been found in persons with unexplained exertion intolerance, possibly via 
mechanisms of endothelial and microcirculatory dysfunction effects on vascular endothelium (66, 76, 77, 79, 
80). In summary, we find that the metabolic changes in patients with ME/CFS are compatible with disrupted 
energetics enforced by tissue hypoxia on exertion. Further investigations should be performed to pursue this 
theory and to identify possible support strategies for improved clinical care.
Possible limitations of the study included metabolite stability and the limited accuracy of global untargeted 
metabolomics (81). The limitations of univariate feature selection for the purpose of clustering and identify-
ing patient subtypes in high dimensional data sets are well known issues in the statistical community (82, 83) 
(Supplemental Data 1). Our comprehensive evaluation of possible cofounders such as sex, BMI, age, diet, or 
medication did not indicate that these were main drivers of the ME/CFS phenotypes, but they may contribute 
to individual variation (Supplemental Data 1). A strength of the study was that statistical analyses were strong-
ly and independently supported by multiple layers of biochemical findings and rationale.
In summary, the study provides a map of  metabolic alterations occurring in patients with ME/CFS. 
We find that the observed changes are compatible with elevated energy strain, for instance, caused by tissue 
hypoxia on exertion. The potential roles of  specific pathways will have to be validated and explored in fur-
ther targeted studies.
Methods
Patients with ME/CFS and HC. In total, 83 patients with ME/CFS and 35 HC were included in this study. 
All patients fulfilled the Canadian consensus criteria for ME/CFS (1). The blood samples were collected 
before intervention (baseline) in 2 separate clinical trials led by Haukeland University Hospital, the “Ritux-
ME” trial (ClinicalTrials.gov NCT02229942, 2014–2017; ref. 45) and the “CycloME” trial (ClinicalTrials.gov 
NCT02444091, 2015–2020; ref. 12). The HC samples were collected (from 2015 to 2017) from subjects with 
no chronic disease or chronic medication — primarily from staff  at the Department of Oncology, Haukeland 
University Hospital, and the Department of Biomedicine, University of Bergen. The HC group was selected 
to approximately match the age and sex distribution of the ME/CFS group. Biometric characteristics for HC 
subjects and patients with ME/CFS are summarized in Table 1, which also contains the data for subgroups of  
patients with ME/CFS annotated to the 3 different metabotypes developed in this study.
Blood samples were collected by venous puncture, processed according to a standardized biobank procedure 
as described in the trial protocols, and stored at –80°C (12, 45). All HC subjects, and 71 patients with ME/CFS, 
were nonfasting on sample collection. The remaining 12 ME/CFS samples were collected after overnight fasting 
and were included to facilitate evaluation of the possible impact of postprandial state. Clinical blood and serum 
analyses were performed according to standard laboratory routines at the hospital.
Global metabolomics and lipidomics. For the metabolite analyses, we included serum samples from all 83 
patients and 35 HC subjects. The analyses were performed by Metabolon Inc. using their standard meth-
ods. The data were acquired applying 2 mass spectrometry–based analytical platforms, one global metabolite 
platform (HD4) providing measurement and identification of  882 compounds covering a broad spectrum of  
molecule and one CLP that assessed 1005 different molecular species of  14 lipid classes. The samples were 
analyzed in daily blocks, with several levels of  sample and data quality control, such as inter-day variation 
correction before data normalization.
Metabolic hormone analyses. For metabolic hormone analyses, we included the same samples, except 5 HC, 
where there was an insufficient amount of serum. The serum samples were diluted, and assays were performed 
according to the manufacturer’s guidelines. Kits based on the Luminex multiplex bead immunoassay technology 
(Luminex 100 instrument, Luminex Corp.) were used to detect FABP4, insulin, HMW adiponectin, and leptin 
(catalog LXSAMH, R&D Systems). ELISA was used to measure FGF21 (catalog DF2100, R&D Systems) and 
C-peptide (catalog DICP00, R&D Systems). Measurements were performed using the Spark microplate reader 
(Tecan Trading AG). Data analysis was done in Excel, GraphPad Prism, and R.
Statistics. All data analyses were performed within the R studio environment (84), using the R programming 
language (85). We first removed xenobiotics and metabolites with more than 25% missing values from the data 
set, and the pattern of missing values was assessed by χ2 and Fisher exact test for group- and sex-wise compari-
sons. Missing values were imputed using the half-minimum method (86). The imputed data were quantile nor-
malized, log2 transformed, and autoscaled. Fold changes, P values (2-tailed Welch’s test) and adjusted P values 
(Benjamini-Hochberg adjustment) were calculated using base functions in R. The autoscaled data were filtered 
based on unadjusted significant metabolites (P < 0.05) to reduce dimensionality in data. Row- and column-wise 
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k-means were performed on significant features to cluster metabolites and samples, and we selected partitions 
of clusters guided by within-cluster sum of square (wss), gap statistic, and the silhouette method. This was visu-
alized in a heatmap using the ComplexHeatmaps package (87), and the resulting clusters were extracted and 
HC organized into a separate HC cluster. These clusters were used as a visualization overlay on an independent 
PCA, and a loading plot was used to visualize loadings from PC1 and PC2 using ggplot2 (88). A univariate 
analysis was performed on the extracted clusters from the multivariate analysis. Metabolites were organized 
into pathways according to annotations provided by Metabolon Inc. The fold changes, P values, and adjusted P 
values from metabolites in each respective pathway were visualized using ggplot2. Selected biometric data were 
correlated to metabolites that displayed uniform changes between clusters using the Spearman method, and P < 
0.05 was set as a cutoff. This was visualized using the ggplot package.
Data from the CLP platform were preprocessed by removing variables with more than 10% of missing 
values in the data set and were imputed by using the minimum observed value for each metabolite. The sam-
ples were organized into the respective clusters obtained from earlier analysis of  HD4, and fold changes, P 
values (Welch’s test), and adjusted P values (FDR) were calculated using base functions within R. Associated 
metadata concerning lipid classes were obtained from Metabolon Inc. and the R package Lipidr (89). The 
resulting data were visualized using the ggplot2. Descriptive statistics were performed using 2-tailed Welch’s 
test for normally distributed data, Mann-Whitney U tests for variables with skewed distributions, and χ2 and 
Fisher’s exact tests for categorical variables (GraphPad Prism). Comparison of  3 or more groups was per-
formed using 1-way ANOVA test.
Study approval. The clinical trials from which the biobank samples were obtained, including samples from 
healthy controls, were approved by the Regional Ethical Committee (Tromsø, Norway; no. 2010/1318-4, no. 
2014/365, and no. 2014/1672). All patients provided written informed consent.
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